Psoriatic arthritis and anti-nuclear factor

Area of Science:

• Rheumatology
• Immunology
• Clinical Medicine

Background:

• Psoriatic arthritis (PsA) is a chronic inflammatory disease.
• Autoantibodies, such as anti-nuclear factor (ANF), are common in autoimmune conditions.
• Understanding ANF prevalence in PsA is crucial for differential diagnosis, especially from rheumatoid arthritis (RA).

Purpose of the Study:

• To determine the prevalence of anti-nuclear factor (ANF) in patients diagnosed with psoriatic arthritis (PsA).
• To compare ANF prevalence in PsA patients with the general population and patients with Sjögren's syndrome.
• To evaluate ANF as a potential differentiating marker between PsA and rheumatoid arthritis (RA).

Main Methods:

• A cohort of 101 patients with psoriatic arthritis was assessed.
• Testing for anti-nuclear factor (ANF) was performed on all participants.
• Results were analyzed for prevalence and compared with existing data.

Main Results:

• Positive anti-nuclear factor (ANF) tests were observed in 7% of the 101 psoriatic arthritis patients.
• Only one patient exhibited a significantly high titre of ANF.
• The overall ANF prevalence in PsA patients was comparable to expected community levels, but notably higher in those with co-existing Sjögren's syndrome.

Conclusions:

• The prevalence of anti-nuclear factor (ANF) in psoriatic arthritis is generally low and similar to the general population.
• A higher prevalence of ANF in psoriatic arthritis patients with Sjögren's syndrome suggests a potential link or shared immunological pathways.
• Anti-nuclear factor (ANF) does not appear to be a strong differentiating serological marker for psoriatic arthritis compared to rheumatoid arthritis, unlike in Sjögren's syndrome.